RxDoctor Payments DataLook up a doctor →

Patrick Murphy, MD

Medical Oncology · Franklin, TNNPI 1487672291

Payments from drug & device makers

$11,433in general payments, 2019–2025

Across 347 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Novartis$1K
  • AVEO Pharmaceuticals, Inc.$1K
  • Johnson & Johnson$787
  • AstraZeneca$614
  • Merck$598
  • plus $5K from 44 others

What the payments were for

  • Consulting fees$2,50022%
  • Food & beverage$7,88769%
  • Education$2142%
  • Other$8327%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,433 in reported general payments places this provider in the 45th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,116,384
Medicare patients
501
Services billed
132,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide33$551,587
XtandiEnzalutamide18$248,735
ErleadaApalutamide16$240,595
IbrancePalbociclib19$215,830
Lenalidomide12$183,230
JakafiRuxolitinib Phosphate12$182,567
NubeqaDarolutamide11$150,073
PromactaEltrombopag Olamine11$143,331
BrukinsaZanubrutinib24$89,484
Imatinib Mesylate20$79,762
EliquisApixaban44$33,644
Abiraterone Acetate23$26,058
XareltoRivaroxaban19$16,502
Anastrozole137$4,678
Letrozole67$1,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$223$551,58733 claims
Johnson & JohnsonErleada, Xarelto$787$257,09735 claims
PfizerIbrance, Eliquis$200$249,47463 claims
Astellas Pharma US IncXtandi$25$248,73518 claims
Incyte CorporationJakafi$277$182,56712 claims
BayerNubeqa$1,813$150,07311 claims
NovartisPromacta$1,439$143,33111 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$45$11013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 101 medical oncology providers in Tennessee.

Other medical oncology in Franklin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →